文献速递泌尿生殖与妇科肿瘤放疗

局限期前列腺癌前列腺内肿瘤结节标准分割与低分割剂量递增:DELINEATE 试验的 5 年疗效与毒性

Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-09-21

DELINEATE 是一项单中心 2 期多队列研究,纳入 265 例中高危局限期前列腺癌患者,256 例接受治疗。患者接受标准分割或中等低分割前列腺调强放疗并对多参数 MRI 识别的病灶进行整合推量。5 年结果显示晚期 RTOG 2 级以上胃肠道和泌尿生殖系统毒性可控,生化/临床失败率低。

要点

  • 1 年晚期 RTOG 2 级以上胃肠道毒性:A 队列 3.6%,B 队列 7.2%,C 队列 8.4%。
  • 5 年晚期 RTOG 2 级以上胃肠道毒性:A 队列 12.8%,B 队列 14.6%,C 队列 20.7%。

核心结论

  • DELINEATE 试验显示 20 次或 37 次分割的局灶推量安全、可耐受且可行。
  • 疗效结果表明放疗后 5 年前列腺癌复发几率低。
  • 正在进行的 3 期随机试验证据有待报告。

研究设计与样本

  • DELINEATE(ISRCTN 04483921)为单中心 2 期多队列研究,纳入美国国家综合癌症网络中危/高危前列腺癌患者。
  • A 队列:前列腺及精囊 74 Gy/37 次;C 队列:前列腺及精囊 74 Gy/37 次加盆腔淋巴结 60 Gy/37 次;B 队列:前列腺及精囊 60 Gy/20 次。
  • A 和 C 队列对多参数 MRI 识别的病灶整合推量 82 Gy,B 队列推量 67 Gy。
  • 共招募 265 例男性,256 例接受治疗(A 队列 55 例,B 队列 153 例,C 队列 48 例)。
  • 各队列中位随访均超过 5 年。

主要发现

  • 1 年晚期 RTOG 2 级以上胃肠道毒性累积发生率:A 队列 3.6%(95%CI 0.9%-13.8%),B 队列 7.2%(95%CI 4%-12.6%),C 队列 8.4%(95%CI 3.2%-20.8%)。
  • 5 年晚期 RTOG 2 级以上胃肠道毒性累积发生率:A 队列 12.8%(95%CI 6.3%-25.1%),B 队列 14.6%(95%CI 9.9%-21.4%),C 队列 20.7%(95%CI 11.2%-36.2%)。
  • 5 年 RTOG 2 级以上泌尿生殖系统毒性累积发生率:A 队列 12.9%(95%CI 6.4%-25.2%),B 队列 18.2%(95%CI 12.8%-25.4%),C 队列 18.2%(95%CI 9.5%-33.2%)。
  • 5 年生化/临床失败率:A 队列 98.2%(95%CI 87.8%-99.7%),B 队列 96.7%(95%CI 91.3%-98.8%),C 队列 95.1%(95%CI 81.6%-98.7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to report 5-year efficacy and toxicity of intraprostatic lesion boosting using standard and hypofractionated radiation therapy. METHODS AND MATERIALS: DELINEATE (ISRCTN 04483921) is a single center phase 2 multicohort study including standardly fractionated (cohort A: 74 Gy/37F to prostate and seminal vesicles [PSV]; cohort C 74 Gy/37F to PSV plus 60 Gy/37F to pelvic lymph nodes) and moderately hypofractionated (cohort B: 60 Gy/20F to PSV) prostate intensity-modulated radiation therapy patients with National Comprehensive Cancer Network intermediate/high-risk disease. Patients received an integrated boost of 82 Gy (cohorts A and C) or 67 Gy (cohort B) to multiparametric magnetic resonance imaging identified lesion(s). Primary endpoint was late Radiation Therapy Oncology Group (RTOG) gastrointestinal (GI) toxicity at 1 year. Secondary endpoints were acute and late toxicity (clinician and patient reported) and freedom from biochemical/clinical failure at 5 years. RESULTS: Two hundred and sixty-five men were recruited and 256 were treated (55 cohort A, 153 cohort B, and 48 cohort C). Median follow-up for each cohort was >5 years. Cumulative late RTOG grade 2+ GI toxicity at 1 year was 3.6% (95% confidence interval [CI], 0.9%-13.8%) (cohort A), 7.2% (95% CI, 4%-12.6%) (cohort B), and 8.4% (95% CI, 3.2%-20.8%) (cohort C). Cumulative late RTOG grade 2+ GI toxicity to 5 years was 12.8% (95% CI, 6.3%-25.1%) (cohort A), 14.6% (95% CI, 9.9%-21.4%) (cohort B), and 20.7% (95% CI, 11.2%-36.2%) (cohort C). Cumulative RTOG grade 2+ genitourinary toxicity to 5 years was 12.9% (95% CI, 6.4%-25.2%) (cohort A), 18.2% (95% CI, 12.8%-25.4%) (cohort B), and 18.2% (95% CI, 9.5%-33.2%) (cohort C). Five-year freedom from biochemical/clinical failure was 98.2% (95% CI, 87.8%-99.7%) (cohort A), 96.7% (95% CI, 91.3%- 98.8%) (cohort B), and 95.1% (95% CI, 81.6-98.7%) (cohort C). CONCLUSIONS: The DELINEATE trial has shown safety, tolerability, and feasibility of focal boosting in 20 or 37 fractions. Efficacy results indicate a low chance of prostate cancer recurrence 5 years after radiation therapy. Evidence from ongoing phase 3 randomized trials is awaited.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tree AC, Satchwell L, Alexander E, et al. Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 36150450. doi:10.1016/j.ijrobp.2022.09.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。